Home/News/Biosphere tenant Iksuda Therapeutics enters licensing agreement with LegoChem Biosciences
Biosphere tenant Iksuda Therapeutics enters licensing agreement with LegoChem Biosciences
LegoChem Biosciences and Iksuda enter Licensing Agreement for Antibody Drug Conjugate program
Iksuda gains worldwide rights to LCBs anti-CD19 ADC LCB73 for development and commercialization in B-cell cancers.
Preclinical data of LCB73 along with clinical outcomes of other CD19-targeted therapies suggest that this ADC represents an effective option for the treatment of various B-cell haematological cancers including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma – thus matching Iksuda’s goal to develop best-in-class ADCs for hard-to-treat cancers with high unmet need.
Iksuda plans to advance LCB73 into the clinic in a the most efficient manner, utilizing its extensive UK and US based ADC expertise to drive pre-clinical and clinical development activities.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.